# NightstaRx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nightstarx

- Industry: Pharmaceuticals
- Headquarters: London, UK
- Total disclosed funding: $120M
- Latest round: Series C (Jun 27, 2017)
- Investors on record: 4

## About

Founded in 2013 and based in London, UK, NightstaRx Limited operates as a developer of gene therapies for inherited retinal diseases such as choroideremia, X-linked retinitis pigmentosa, and best vitelliform macular dystrophy.

## Funding rounds

- Series C, Jun 27, 2017, $58M — New Enterprise Associates, Wellington Management, Redmile Group, Syncona
- Series B, Nov 5, 2015, $35M — New Enterprise Associates, Syncona
- Series A, May 21, 2014, $27M — Syncona

## Investors

- Syncona (https://capitalatlas.ai/funds/syncona) — Series A, Series B, Series C
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C